FRANCE- Dsm-firmenich, a leading global innovator in nutrition, health, and beauty, has completed the acquisition of French-based postbiotics pioneer Adare Biome for an enterprise value of €275 (US$299.64) million.
“The Adare Biome teams will enable us to accelerate the creation of next-generation biotics to support the health of people and animals,” said Philip Eykerman, President of Health, Nutrition & Care.
Postbiotics are a rapidly emerging segment of the gut health market, offering longer shelf-life and greater application versatility than probiotics while providing substantiated health benefits.
A growing body of robust scientific evidence supports the idea that they represent the next wave of opportunity in the gut health market.
“Adare Biome, as a global leader in the research and manufacturing of postbiotics with over a century of pioneering science in its heritage, is a perfect fit for dsm-firmenich that will complement three of our four Business Units,” Eykerman remarked.
According to Eykerman, the Adare Biome teams will greatly help the ingredients provider in driving its ‘Health from the Gut’ strategy and accelerate the creation of next-generation biotics to support the health of people and animals.
“We are excited about the new opportunities this move will unlock, as dsm-firmenich’s strong global presence and reach in local markets will enable us to deliver Adare Biome products to customers in a faster, more efficient way to bring the proven benefits of postbiotics to a wider range of people around the world,” Eykerman added.
Dsm-firmenich intends to extend the availability of Adare Biome’s over-the-counter postbiotic supplement for relieving gut upsets, Lactéol, through its B2C unit, i-Health.
Additionally, further development of postbiotic B2B ingredients will include opportunities in dietary supplements, early life nutrition, medical nutrition, and nutritional improvement for the under-nourished.
Moreover, the acquisition of Adare Biome will also position dsm-firmenich as a leader in the growing microbiome management market for pets and expand its animal health range, where the stability of postbiotics means that they can be incorporated into premix feed solutions.
“Dsm-firmenich is the ideal company to take Adare Biome to the next level and realize the growth potential of postbiotics. They have the infrastructure, together with strong commercialization and science capabilities, to scale the significant scientific research that we’ve achieved over the years,” Tom Sellig, CEO of Adare Pharma Solutions, commented.
Tom Sellig also added that dsm-firmenich’s purpose of bringing progress to life resonates strongly with the team at Adare Biome and was looking forward to contributing to the realization of this purpose as part of the dsm-firmenich family.